AbbVie terminated agreement with Caribou Biosciences regarding development of next-generation, off-the-shelf CAR-T cell therapies October 3, 2023
AbbVie is terminating its agreement with I-Mab to develop certain CD47 antibody compounds, including the programme’s lead drug lemzoparlimab October 3, 2023
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA® September 26, 2023
1ST Biotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate FB849 in Combination With KEYTRUDA September 26, 2023
Collaborative Trial to Study PP2A Inhibitor, LB-100, Plus Dostarlimab, in Clear-Cell Ovarian Cancer announced September 26, 2023
Boundless Bio Announces Clinical Trial Collaboration & Supply Agreement with Taiho Oncology to Evaluate LYTGOBI + BBI-355 in Patients with FGFR Amplified Solid Tumors September 26, 2023
Boundless Bio Announces Clinical Trial Collaboration & Supply Agreement with Lilly to Evaluate VERZENIO + BBI-355 in Patients with CDK4/6 Amplified Solid Tumors September 26, 2023
Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-treat Cancers September 26, 2023
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091 September 19, 2023
Ryvu Therapeutics’ Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advanced Diffuse Large B-Cell Lymphoma (DLBCL) September 19, 2023
Nurix Announces Strategic Collaboration with Seagen Combining Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance a New Class of Cancer Therapeutics September 19, 2023
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics September 19, 2023
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology September 19, 2023
KSQ Therapeutics and CTMC Announce Strategic Collaboration to Accelerate the Development of Novel Engineered Tumor Infiltrating Lymphocyte (eTIL) Therapies for the Treatment of Solid Tumors September 13, 2023
Portage Biotech announces collaboration with Merck to evaluate two next-generation adenosine antagonists in combination with Keytruda® in solid tumors September 13, 2023
OncoNano and Regeneron Enter into Clinical Trial Supply Agreement for Use of Libtayo® (cemiplimab) in ONM-501 Study September 13, 2023
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers September 6, 2023
CARsgen Collaborates with Moderna to Evaluate CT041 in Combination with an mRNA Cancer Vaccine September 1, 2023
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers September 1, 2023
Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial September 1, 2023
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience August 23, 2023
Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida’s Commitment to Redefining Cancer Cell Therapy August 16, 2023
VANFLYTA® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML August 16, 2023
